In preclinical models of KIT K641E-mutant melanoma, a hybrid biomimetic nanovaccine combining tumor and dendritic cell membranes significantly enhanced dendritic cell maturation, T-cell activation, and inhibited tumor growth. Here, KIT is linked to melanoma.